The expression of STC2 is closely related to the prognosis of tumor patients, and its high expression leads to poor prognosis in patients with breast cancer (Esseghir et al., 2007), nasopharyngeal carcinoma (Lin et al., 2014), colorectal cancer (Ieta et al., 2009), and renal cell carcinoma (Meyer et al., 2009). This evidence concerns the gene STC2 and colorectal cancer.